Source comparison
Tesamorelin Results After 2 Weeks: Clinical vs Aesthetic Comparison
Serum IGF-1 levels Elevated 40–60% above baseline Stable at 50–70% above baseline Hepatic synthesis peaks within 7–10 days Blood test required. Not visible or subjectively felt Visceral adipose tissue (VAT) area 0–2% reduction (within measurement error) 12–18%
This comparison does not assign a generated winner or score.
- Serum IGF-1 levels
- Elevated 40–60% above baseline
- Stable at 50–70% above baseline
- Hepatic synthesis peaks within 7–10 days
- Blood test required. Not visible or subjectively felt
- Visceral adipose tissue (VAT) area
- 0–2% reduction (within measurement error)
- 12–18% reduction via CT imaging
- Lipolysis begins week 4–6, accelerates through month 3
- Requires CT or MRI quantification. Waist circumference unreliable at week 2
- Fasting insulin sensitivity
- Minimal change or transient worsening
- 15–25% improvement in HOMA-IR index
- Counter-regulatory GH effect dominates early; IGF-1 and VAT loss drive late improvement
- HOMA-IR calculation from fasting glucose and insulin. Rarely tracked outside clinical trials
- Subjective sleep quality
- 30–40% of users report noticeable improvement
- Sustained improvement in most responders
- GH-mediated enhancement of slow-wave sleep begins within 10–14 days
- Self-reported. No objective marker needed
- Body composition (DEXA scan)
- No statistically significant change in lean or fat mass
- Mean 1.2 kg visceral fat loss, 0.4 kg lean mass gain
- Protein synthesis and lipolysis are slow, cumulative processes
- DEXA required for accurate measurement. Scale weight and visual assessment miss early changes entirely